Compare MGNI & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGNI | PHVS |
|---|---|---|
| Founded | 2007 | 2015 |
| Country | United States | Switzerland |
| Employees | 514 | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.8B |
| IPO Year | 2014 | 2020 |
| Metric | MGNI | PHVS |
|---|---|---|
| Price | $12.89 | $29.56 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 11 |
| Target Price | $25.22 | ★ $41.82 |
| AVG Volume (30 Days) | ★ 1.8M | 205.9K |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 493.75 | N/A |
| EPS | ★ 0.95 | N/A |
| Revenue | ★ $156,414,000.00 | N/A |
| Revenue This Year | $6.28 | N/A |
| Revenue Next Year | $9.76 | N/A |
| P/E Ratio | $13.72 | ★ N/A |
| Revenue Growth | ★ 25.45 | N/A |
| 52 Week Low | $10.82 | $15.51 |
| 52 Week High | $26.65 | $30.24 |
| Indicator | MGNI | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 51.82 | 58.51 |
| Support Level | $11.07 | $24.73 |
| Resistance Level | $14.30 | N/A |
| Average True Range (ATR) | 0.58 | 1.44 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 52.58 | 89.53 |
Magnite is a supply-side advertising platform that provides technology and yield management solutions to content publishers, enabling them to monetize their digital advertising inventory. Magnite receives a percentage of all advertising inventory that it sells. 43% of Magnite's revenue is derived from connected television, or CTV, streaming platforms, 40% from mobile applications, and the remainder from general websites. Beyond the typical monetization responsibilities inherent to an SSP, Magnite also provides upstream advertising servers to CTV publishers, allowing them to have granular control over direct-sold, programmatic guaranteed, and open-auction logic. Magnite competes with other independent SSPs, supply path optimization solutions, and closed ecosystems like Meta.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.